Tirzepatide
A dual-hormone incretin that activates both GIP and GLP-1 receptors, producing greater average weight reduction and metabolic control than single-target therapies.
Tirzepatide Biological Classification
A dual-hormone incretin that activates both GIP and GLP-1 receptors, producing greater average weight reduction and metabolic control than single-target therapies.
Dual Receptor Binding
Binds both GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion more effectively than single agonists.
Adipose Tissue Regulation
GIP activity increases insulin sensitivity in fat cells and promotes healthy lipid storage rather than ectopic fat accumulation.
Central Satiety Enhancement
Synergistic signaling in the hypothalamus and hindbrain produces deeper, more consistent appetite reduction.
What is Tirzepatide?
Tirzepatide is a synthetic dual incretin peptide that activates both Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. It is commercialized under the brand names Mounjaro and Zepbound.
Why are people interested in it?
Tirzepatide was the first drug to demonstrate average weight loss exceeding 20% in large-scale clinical trials. By activating two metabolic hormone pathways at once, it achieves superior blood sugar control and greater weight reduction than GLP-1-only medications with comparable or slightly milder digestive side effects.
Primary Research Categories
- Incretin analogues
- Approved drug substances
How does it work in the body?
Tirzepatide leverages synergistic incretin biology. While GLP-1 primarily acts on brain satiety and pancreatic insulin, GIP receptors are abundant in adipose (fat) tissue and the brain, enhancing lipid metabolism and softening nausea.
Dual Incretin Mechanism
GIP + GLP-1 Dual Receptor Synergy
GLP-1 Arm
- • Slows stomach gastric emptying rate
- • Suppresses appetite centers in hypothalamus
- • Glucose-dependent insulin release
GIP Arm
- • Enhances insulin sensitivity in white adipose tissue
- • Buffers digestive nausea associated with high GLP-1
- • Amplifies central metabolic satiety signaling
Dual Receptor Binding
Binds both GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion more effectively than single agonists.
Adipose Tissue Regulation
GIP activity increases insulin sensitivity in fat cells and promotes healthy lipid storage rather than ectopic fat accumulation.
Central Satiety Enhancement
Synergistic signaling in the hypothalamus and hindbrain produces deeper, more consistent appetite reduction.
What has actually been demonstrated in humans?
Tirzepatide has been validated in the extensive SURPASS (diabetes) and SURMOUNT (obesity) Phase 3 trial programs, demonstrating average weight losses of 15% to 22.5% across varying dose tiers.
SURMOUNT-1 Phase 3 Trial (Jastreboff et al., NEJM 2022)
Duration: 72 weeks · Population: 2,539 adults with obesity without diabetesPublished Finding: Mean percentage weight reductions were 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) compared to 3.1% with placebo. Over 60% of participants on 15 mg lost at least 20% of their body weight.
Pharmaceutical Reality vs. Unregulated Research Chemicals
Tirzepatide is a prescription medicine that requires gradual titration over months to prevent severe gastrointestinal side effects. Unregulated compounded or online research versions carry significant dosing variance and regulatory warnings.
What is still uncertain or unknown?
Long-term cardiovascular outcome trial results (SURPASS-CVOT) are still completing. The distinct mechanistic contribution of GIP vs GLP-1 in humans continues to be investigated in clinical pharmacology.
Clinical Perspectives & Expert Discussions
Explore all perspectivesWhat identifiable clinicians, researchers, and professional bodies have publicly discussed regarding Tirzepatide.
Dr. Peter Attia, M.D.
M.D. (Stanford University School of Medicine); former surgical oncology fellow at National Cancer Institute (NIH); author of Outlive: The Science and Art of Longevity; host of The Drive podcast.
Dr. Attia publicly analyzes the metabolic effects of GLP-1 and multi-agonist incretins, cautioning that rapid scale weight loss often includes 25% to 40% skeletal muscle and lean organ mass loss if progressive heavy resistance training and adequate dietary protein (roughly 1 gram per pound of target body weight) are not strictly prioritized.
Dr. Tyna Moore, N.D., D.C.
Licensed Naturopathic Physician (N.D., National University of Natural Medicine) and Chiropractor (D.C., University of Western States) in Oregon; host of The Dr. Tyna Show.
Dr. Moore discusses an alternative clinical approach advocating for conservative starting doses and slower titration schedules than standard pharmaceutical escalation protocols. She argues that starting with lower amounts allows patients to evaluate GI tolerance, manage autonomic nervous system adaptation, and achieve metabolic anti-inflammatory benefits without triggering rapid muscle catabolism.
The Endocrine Society
Global medical organization representing over 18,000 endocrinologists, researchers, and clinical educators.
Consensus clinical guidelines recommend high-potency incretin receptor agonists (semaglutide, tirzepatide) as foundational adjuncts to lifestyle intervention for adults with obesity or weight-related comorbidities. The guideline emphasizes structured monthly dose escalation, long-term adherence to sustain metabolic benefits, and cautions against abrupt discontinuation, which typically results in weight regain.
Dosing Reference
Open Tirzepatide Dosing ReferenceAn approved dual GIP/GLP-1 receptor agonist with authoritative prescribing labels. Compounded or research-grade copies are chemically distinct and lack FDA safety verification.
Therapept separates official product labels, published clinical study interventions, animal research, clinical references, and community-reported ranges — never blended into one number.
Research at a Glance
Open the full evidence file (3 records)3 records in this file
- CLINICAL TRIAL2
- REGULATORY1
Publication span: 2021–2023
What Has Actually Been Studied
- Drugs@FDA — Mounjaro (NDA 215866), Zepbound (NDA 217806) (Drugs@FDA, 2023) — Approved-drug labelling.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) (New England Journal of Medicine, 2022) — Randomised, double-blind, placebo-controlled trial.
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) (New England Journal of Medicine, 2021) — Randomised, open-label, active-controlled trial.
What is Still Unknown
What we know
- Two FDA-approved products exist (Mounjaro, Zepbound). SURMOUNT-1 and SURPASS-2 are published Phase 3 trials in NEJM.
- SURPASS-2 compared tirzepatide with semaglutide 1 mg in type 2 diabetes, not with the 2.4 mg STEP dose.
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
- As with semaglutide, approved-product trials do not describe compounded or research-chemical copies.
Preparation and Handling
Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.
United States Regulatory Status
FDA-approved drug substance
Application: NDA 215866 (Mounjaro), NDA 217806 (Zepbound)
Approved Indication: Marketed in the United States as two approved prescription products: Mounjaro (type 2 diabetes mellitus) and Zepbound (chronic weight management).
- Approved prescription drug substance. Mounjaro approved 13 May 2022; Zepbound 8 November 2023.
- Not placed in FDA's Category 2 of bulk substances that may present significant safety risks.
- FDA proposed in April 2026 to exclude tirzepatide from the 503B bulks list.
Technical Chemical SpecificationsClick to view CAS, sequence, and molecular formulas
- Molecular weight
- 4813.53 Da (FDA label); 4813 g/mol (PubChem)
- Sequence length
- 135 chars
- CAS number
- 2023788-19-2
- PubChem CID
- 156588324
- Compound class
- Dual GIP and GLP-1 receptor agonist
- Sequence
- 39-residue GIP-based analogue with Aib at positions 2 and 13, a C-terminal amide, and Lys20 attached to eicosanedioic acid via a linker
- Molecular formula
- C225H348N48O68
- Molecular weight
- 4813.53 Da (FDA label); 4813 g/mol (PubChem)
- CAS number
- 2023788-19-2
- PubChem CID
- 156588324
Sources
- PubChem CID 156588324
- Drugs@FDA — approved drug products
- Drugs@FDA — NDA 215866 (Mounjaro)Section 11 (Description) states the sequence modifications and molecular weight.
Last reviewed 3 September 2026 · Compiled by Therapept Editorial · How these records are built